Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jun 14;15(1):2220466. doi: 10.1080/19420862.2023.2220466

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 The Author(s). Published with license by Taylor & Francis Group, LLC.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.

PMC Copyright notice

Figure 5. — Immune cell infiltration in tumor tissue after TS-L6 treatment.

Six days after 20 mg/kg TS-L6 administration, tumor tissues were isolated, fixed, and embedded for IHC. a, A tumor from the TS-L6 treatment group exhibited more CD86+ cells compared with saline control and the TS treatment group. b, The CD3+ T cells (upper) and CD8+ T cells (bottom) infiltration was enhanced after TS-L6 treatment. c, Innate immune cells, mainly macrophages, showed decreased CD163 and (upper) CD206 (bottom) expression in TS-L6 treated tumors. D, The amounts of CD86, CD3, CD8, CD163, and CD206 positive cells were collected and the statistical differences between the TS and TS-L6-treated groups were analyzed using Student’s t test. Five independent tests were performed, and the data are shown as mean and SD.

ns, *, ** and *** represented no significance, P<0.05, 0.01, and 0.001, respectively.